On Thursday, in the course of current trade, Shares of Mack Cali Realty Corp (NYSE:CLI), dropped -0.03%, and is now trading at $20.25.
Mack-Cali Realty Corporation declared that Brown Brothers Harriman (BBH) has signed a new 11-year lease for 114,798 square feet at the Company’s Harborside Plaza 5 in Jersey City, New Jersey.
Moving within the Jersey City Waterfront market, BBH will transfer over 500 employees to their new location. Harborside Plaza 5 is a 977,225-square-foot, class A office tower located in the heart of Jersey City. The building features landscaped outdoor seating areas, restaurants, and breathtaking, panoramic views of the Manhattan skyline and New York Harbor. This premier asset is presently 99 percent leased.
Mack-Cali Realty Corporation is a real estate investment trust (REIT). It engages in the leasing, administration, acquisition, development, and construction of commercial real estate properties in the United States.
During an Afternoon trade, Shares of Apache Corporation (NYSE:APA), dipped -1.73%, and is now trading at $46.50.
Apache Corporation, will release its second-quarter 2015 results at 7 a.m. Central time on Thursday, Aug. 6, 2015, followed by a conference call to talk about its results at 1 p.m. Central time.
Apache Corporation, an independent energy company, explores, develops, and produces natural gas, crude oil, and natural gas liquids. It operates onshore and offshore assets primarily in the Permian Basin, the Anadarko basin in western Oklahoma, and the Texas Panhandle, Gulf Coast areas of the United States, in addition to in Western Canada.
Shares of Array Biopharma Inc (NASDAQ:ARRY), during its Thursday’s current trading session fell -1.23%, and is now trading at $6.57.
AstraZeneca, declared that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally compriseent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing.
Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Finally, DryShips Inc. (NASDAQ:DRYS), lost -3.23% Thursday.
DryShips, declared the agreement with one of its charterers to write-off about $16.5 million in overdue receivables related to charter hire payments due on 11 vessels on time charter. As part of the transaction, the charterer has agreed to forgo the exercise of certain “in-the-money” purchase options related to 7 vessels on time charter and provide new charters for 11 vessels at $12,500/day gross with 50-50 profit sharing starting as of June 1, 2015 and for an average period of about 4.5 years.
DryShips Inc. provides ocean transportation services for drybulk and petroleum cargoes, and offshore deepwater drilling services. The company operates through Drybulk, Tanker, and Drilling segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
